Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations
Brandon J. Manley(Moffitt Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Paul Russo(Memorial Sloan Kettering Cancer Center), Yusuke Sato(Tokai University), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Jozefina Casuscelli(LMU Klinikum), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Daniel Tennenbaum(Memorial Sloan Kettering Cancer Center), Mazyar Ghanaat(Memorial Sloan Kettering Cancer Center), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Ed Reznik(Icahn School of Medicine at Mount Sinai), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Mahyar Kashan(Memorial Sloan Kettering Cancer Center)
Urologic Oncology Seminars and Original Investigations
November 10, 2017
Cited by 28
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k